文章：

多线治疗滤泡性淋巴瘤的疾病负担：意大利真实世界数据分析

Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis

原文发布日期：2 September 2023

DOI: 10.3390/cancers15174403

类型: Article

开放获取: 是

英文摘要：

This real-world analysis investigated patients with follicular lymphoma in Italy receiving three or more treatment lines (≥3L), focusing on therapeutic pathways with their rebounds on healthcare resource consumptions and costs. Data were retrieved from administrative databases from healthcare entities covering about 13.3 million residents. Adults diagnosed with follicular lymphoma were identified between January 2015 and June 2020, and among them 2434 patients with ≥3L of treatment during the data availability interval (January 2009 to June 2021) were included. Of them, 1318 were in 3L, 494 in 4L and 622 in ≥5L. A relevant proportion of patients (12–32%) switched to a later line within the same calendar year. At 3-year follow-up (median), 34% patients died. Total mean annual expenses were euro 14,508 in the year preceding inclusion and rose to euro 21,081 at 1-year follow-up (on average euro 22,230/patient/year for the whole follow-up), with hospitalization and drug expenses as weightiest cost items. In conclusion, the clinical and economic burden of follicular lymphoma increases along with later treatment lines. The high mortality rates indicate that further efforts are needed to optimize disease management.

摘要翻译： 

这项真实世界分析研究了意大利接受三线及以上治疗（≥3L）的滤泡性淋巴瘤患者，重点关注其治疗路径及其对医疗资源消耗和成本的影响。数据来源于覆盖约1330万居民的医疗管理机构行政数据库。研究纳入2015年1月至2020年6月期间确诊的滤泡性淋巴瘤成年患者，其中2434例在数据可及期（2009年1月至2021年6月）内接受过≥3L治疗。其中1318例处于3L阶段，494例处于4L阶段，622例处于≥5L阶段。相当比例患者（12-32%）在同一年度内转入后续治疗线。中位随访3年期间，34%的患者死亡。患者纳入前一年的年均总费用为14,508欧元，在1年随访时上升至21,081欧元（整个随访期间患者年均费用为22,230欧元），住院和药物费用构成最主要的支出项目。综上所述，滤泡性淋巴瘤的临床和经济负担随治疗线数后移而增加。高死亡率提示需要进一步优化疾病管理策略。

原文链接：

Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis